Novel Small Molecules targeting RNA, RNA-binding Proteins, or RNA-modifying Proteins, for Use in Oncology, Neuroscience, and Inflammation

NextRNA Therapeutics, a biotechnology company developing small molecule therapeutics targeting long non-coding RNAs and RNA-binding proteins is seeking novel small molecules that target RNA, RNA-binding proteins or RNA-modifying proteins for treating diseases in oncology, neuroscience, and inflammation. 

In Scope:

• Ideally genetically driven disease mechanisms
• RNA targets can be long non-coding RNAs, non-coding RNAs (e.g. microRNAs), or messenger RNAs. Protein targets can be RNA-binding proteins, RNA-modifying proteins, or DNA-binding proteins (e.g. Transcription Factors) 
• Therapeutic approaches of interest: small molecules altering the function of targets (inhibitor, activator, degrader), with a particular interest in functional small molecules modulating RNA-Protein interactions
• Therapeutics for treating solid tumors with high unmet need are of highest priority (e.g. Breast cancer, Gastrointestinal cancers [such as Colorectal, Pancreatic, Gastroesophageal cancer], Glioblastoma, Small cell lung cancer) 
• Therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuromuscular disorders, as well as therapeutics for autoimmune disease and inflammatory disorders
• Oral delivery is of highest interest 

Developmental Stages of Interest:

• Opportunities from late hit-to-lead up to drug candidate stage are of interest 
• Demonstration of target engagement in cell models is a prerequisite 

Out of Scope:

• Platforms for finding RNA targets or screening small molecules 
• Treatments for neuro-psychiatric or mood disorders 
• Therapeutics that are not small molecules (e.g. peptides, antisense oligonucleotides, etc.) 

Submission and Collaboration Information

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. In submitting to this campaign, you confirm that your submission contains only non-confidential information. NextRNA Therapeutics is seeking exclusive worldwide licensing rights.